findmyKOL
Clinical trialNCT06971939RecruitingPhase 4Interventional

Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants

SponsorNeurotech PharmaceuticalsEnrollment285Macular Telangiectasia Type 2 (MacTel)
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

26 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia
  • Cerulea

    East Melbourne, Australia

    Penelope Allen, MD
    Recruiting
  • Lion'S Eye Institute

    Perth, Australia

    Ian Constable, MD
    Recruiting
  • Sydney Eye Hospital

    Sydney, Australia

    Elisa Cornish, MD
    Recruiting
United States
  • Scripps Health

    La Jolla, California, United States

    Richard Lin, MD
    Not, yet, recruiting
  • Jules Stein Eye Institute/ucla

    Los Angeles, California, United States

    Colin McCannel, MD
    Not, yet, recruiting
  • Stanford University School of Medicine

    Palo Alto, California, United States

    Diana Do, MD
    Not, yet, recruiting
  • Bay Area Retina Associates

    Walnut Creek, California, United States

    Roger Goldberg, MD
    Recruiting
  • Colorado Retina

    Lakewood, Colorado, United States

    Murtaza Adam, MD
    Recruiting
  • Bascom Palmer

    Miami, Florida, United States

    Philip Rosenfield, MD
    Not, yet, recruiting
  • Emory Eye Center

    Atlanta, Georgia, United States

    Jiong Yan, MD
    Recruiting
  • Northwestern University

    Chicago, Illinois, United States

    Amani Fawzi, MD
    Not, yet, recruiting
  • National Eye Institute

    Bethesda, Maryland, United States

    Tiarnan Keenan, MD
    Not, yet, recruiting
  • Cumberland Valley Retina Consultants

    Frederick, Maryland, United States

    David Warrow, MD
    Not, yet, recruiting
  • Massachusetts Eye and Ear Infirmary, Retina Service

    Boston, Massachusetts, United States

    Dean Eliott, MD
    Not, yet, recruiting
  • Foundation for Vision Research

    Grand Rapids, Michigan, United States

    Liliya Sutherland, MD
    Recruiting
  • Retina Consultants of Minnesota

    Minneapolis, Minnesota, United States

    Abdhish Bhavsar, MD
    Not, yet, recruiting
  • Envision Ocular, Llc

    Bloomfield, New Jersey, United States

    Patrick Higgins, MD
    Recruiting
  • Cincinnati Eye Institute

    Cincinnati, Ohio, United States

    Lucas Lindsell, MD
    Recruiting
  • Retina Associates of Cleveland, Inc.

    Cleveland, Ohio, United States

    Joseph Coney, MD
    Recruiting
  • Retina Northwest, P.C.

    Portland, Oregon, United States

    Michael Lee, MD
    Not, yet, recruiting
  • Scheie Eye Institute

    Philadelphia, Pennsylvania, United States

    Alexander Brucker, MD
    Not, yet, recruiting
  • Southeastern Retina Associates, P.C.

    Knoxville, Tennessee, United States

    Stephen Perkins, MD
    Recruiting
  • Retina Center of Texas

    Dallas, Texas, United States

    Jawad Qureshi, MD
    Recruiting
  • Texas Retina Associates

    Dallas, Texas, United States

    Ashkan Abbey, MD
    Recruiting
  • Retina Consultants of Texas

    Houston, Texas, United States

    Charles Wykoff, MD
    Recruiting
  • University of Utah John A. Moran Center

    Salt Lake City, Utah, United States

    Paul Bernstein, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 Nov 2025
Primary completion
15 Jan 2032
Completion
15 Jan 2032
Last update posted
1 Jun 2026
Registered enrollment
285
Registry id
NCT06971939

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.